IgA Nephropathy Secondary to Ipilimumab Use
Ipilimumab is a human monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 approved for the treatment of non-small-cell lung cancer (NSCLC) and other malignancies. Despite a high prevalence of other immune-related adverse events (irAEs), checkpoint inhibitor (CPI)-related nephro...
Guardado en:
Autores principales: | Sean C. Dougherty, Nisa Desai, Helen P. Cathro, Amanda Renaghan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Karger Publishers
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c509c83f285d4cb4aa1d2601709d1b42 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Hydroxychloroquine in IgA nephropathy: a systematic review
por: Gabriel Stefan, et al.
Publicado: (2021) -
IgA nephropathy with wilson's disease: A case report and literature review
por: Gaurav Bhandari, et al.
Publicado: (2021) -
Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy
por: Yebei Li, et al.
Publicado: (2021) -
Normotensive and hypertensive Immunoglobulin a nephropathy with ischemic renal injury: clinicopathological characteristics and prognosis
por: Yongli Wang, et al.
Publicado: (2021) -
Identification of miRNA-mRNA network and immune-related gene signatures in IgA nephropathy by integrated bioinformatics analysis
por: Shi-Yao Wei, et al.
Publicado: (2021)